计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G610530-5mg |
5mg |
期货 ![]() |
| |
| G610530-25mg |
25mg |
期货 ![]() |
|
| 别名 | GDC0214;iJak-381;RG-6151;RG6151 |
|---|---|
| 英文别名 | GDC0214;iJak-381;RG-6151;RG6151 |
| 规格或纯度 | Moligand™ |
| 英文名称 | GDC-0214 |
| 作用类型 | 抑制剂 |
| 作用机制 | Janus 激酶 1 抑制剂;Janus 激酶 2 抑制剂;Janus 激酶 3 抑制剂;酪氨酸激酶 2 抑制剂 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| INCHI | 1S/C28H28ClF2N9O3/c1-37(10-2-8-32)19-6-12-38(13-7-19)24(41)17-39-16-22(35-27(42)21-15-34-40-11-3-9-33-26(21)40)25(36-39)20-14-18(29)4-5-23(20)43-28(30)31/h3-5,9,11,14-16,19,28H,2,6-7,10,12-13,17H2,1H3,(H,35,42) |
| InChi Key | ITNFPSJJBYFVEA-UHFFFAOYSA-N |
| Smiles | CN(CCC#N)C1CCN(CC1)C(=O)CN2C=C(C(=N2)C3=C(C=CC(=C3)Cl)OC(F)F)NC(=O)C4=C5N=CC=CN5N=C4 |
| Isomeric SMILES | CN(CCC#N)C1CCN(CC1)C(=O)CN2C=C(C(=N2)C3=C(C=CC(=C3)Cl)OC(F)F)NC(=O)C4=C5N=CC=CN5N=C4 |
| PubChem CID | 118522534 |
| 分子量 | 612 |
| 分子量 | 612.000 g/mol |
|---|---|
| XLogP3 | 2.600 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 10 |
| 精确质量Exact Mass | 611.197 Da |
| 单同位素质量Monoisotopic Mass | 611.197 Da |
| 拓扑极表面积Topological Polar Surface Area | 134.000 Ų |
| 重原子数Heavy Atom Count | 43 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1010.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Braithwaite IE, Cai F, Tom JA, Galanter JM, Owen RP, Zhu R, Williams M, McGregor AG, Eliahu A, Durk MR et al.. (2021) Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.. J Allergy Clin Immunol, 148 (3): (783-789). [PMID:33744327] |
| 2. Dengler HS, Wu X, Peng I, Rinderknecht CH, Kwon Y, Suto E, Kohli PB, Liimatta M, Barrett K, Lloyd J et al.. (2018) Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma.. Sci Transl Med, 10 (468): (eaao2151). [PMID:30463918] |